NeoGenomics (NEO)
(Delayed Data from NSDQ)
$13.53 USD
-0.01 (-0.07%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $13.52 -0.01 (-0.07%) 7:22 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.53 USD
-0.01 (-0.07%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $13.52 -0.01 (-0.07%) 7:22 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
Zacks News
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
NeoGenomics (NEO) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 500.00% and -2.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate NeoGenomics (NEO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
NeoGenomics (NEO) Looks Good: Stock Adds 5.5% in Session
by Zacks Equity Research
NeoGenomics (NEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
ANIK vs. NEO: Which Stock Is the Better Value Option?
by Zacks Equity Research
ANIK vs. NEO: Which Stock Is the Better Value Option?
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
NeoGenomics (NEO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 55.56% and 1.01%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: NeoGenomics (NEO) Q2 Earnings Expected to Decline
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics (NEO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of -200.00% and -0.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 42.86% and 2.31%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Healthcare ETF (IHF) Tops in October: 5 Best Stocks
by Sweta Killa
Inside the best performing stocks of the top ETF of October.
NeoGenomics (NEO) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 16.67% and 5.50%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) Meets Q2 Earnings Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and 5.03%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics (NEO) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
NeoGenomics (NEO) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 40.00% and 9.13%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Ready Capital, Gladstone, NeoGenomics, Digi and Paramount
by Zacks Equity Research
Zacks.com featured highlights include: Ready Capital, Gladstone, NeoGenomics, Digi and Paramount
NeoGenomics (NEO) Reports Next Week: What to Know Ahead of the Release
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Breakout Stocks for Stellar Returns
by Swarup Gupta
This method involves zeroing in on stocks whose prices vary within a narrow band.
Is NeoGenomics (NEO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (NEO) Outperforming Other Medical Stocks This Year?
Is NeoGenomics (NEO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (NEO) Outperforming Other Medical Stocks This Year?
NeoGenomics (NEO) Stock Moves -1.04%: What You Should Know
by Zacks Equity Research
NeoGenomics (NEO) closed the most recent trading day at $11.46, moving -1.04% from the previous trading session.